TMIST: A Three-Dimensional Approach to Early Breast Cancer Detection

This event has been CANCELLED.

During this event, Worta McCaskill-Stevens, M.D., M.S., Etta D. Pisano, M.D., and Carolyn D. Runowicz, M.D., will give an overview of the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) study. TMIST is a randomized breast cancer screening trial that aims to help researchers learn about the best ways to find breast cancer in women who have no symptoms. It compares both Food and Drug Administration–approved types of digital mammography: standard digital mammography (2-D) and a newer technology called tomosynthesis mammography (3-D).

The trial hopes to introduce a new screening technology, increase evidence-based information to guide women and providers about benefits and harms in the current screening environment, and evolve evidence with respect to screening intervals. The overarching goal is to reduce the incidence of late-stage cancers rather than to simply increase the incidence of early-stage disease.

Another important aspect of the trial is to build a tissue bank for future research. All women who join the trial are required to submit tissue samples, such as blood and swabs of cells from inside their mouths. Researchers hope that the information from these tissue samples will help decide the best ways to screen for breast cancer in the future by taking a person’s genetics and other personal risk factors into account.

Please note that continuing medical education (CME) credits are available for this seminar. To obtain credit, please follow the directions on the registration site

For questions, please contact Pamela Maxwell.

Individuals with disabilities who need reasonable accommodation to participate in this event should contact Pamela Maxwell (, and/or the Federal Relay Service (1-800-877-8339) 3 days in advance of the event date to discuss accommodation needs.

Attendance Restriction: NIH Staff Only